Table 1.
Comparison of general clinical data of EDM and MDM patients
| Variables | EDM | MDM | P |
|---|---|---|---|
| n | 73 | 34 | |
| Male [n,(%)] | 56 (76.7) | 22 (64.7) | 0.536 |
| Age(yrs) | 81.08 ± 5.36 | 56.68 ± 5.24 | < 0.001 |
| BMI (kg/m) | 25.68 ± 3.23 | 27.29 ± 3.50 | 0.021 |
| SBP (mmHg) | 142.03 ± 18.20 | 135.26 ± 23.12 | 0.139 |
| DBP (mmHg) | 68.25 ± 9.21 | 77.47 ± 14.41 | 0.001 |
| Anti-diabetes drugs | |||
| sulfonylurea [n, (%)] | 13 (17.8) | 6 (17.6) | 0.507 |
| Insulin [n, (%)] | 43 (58.9) | 19 (55.9) | 0.528 |
| Others [n, (%)] | 17 (35.6) | 9 (26.5) | 0.223 |
| Metformin | 10 | 7 | 0.3640 |
| α-glucosidase inhibitor | 5 | 1 | 0.6621 |
| DPP 4 inhibitors | 1 | 1 | 0.5366 |
| TZD | 1 | 0 | 1.0000 |
| Other drugs | |||
| CCB | 12 | 3 | 0.3787 |
| ACEI | 11 | 3 | 0.5410 |
| ARB | 17 | 5 | 0.3064 |
| CCB + ACEI | 0 | 2 | 0.0989 |
| CCB + ARB | 18 | 5 | 0.2433 |
| ASP | 28 | 12 | 0.7605 |
| Statins/Brates | 17 | 7 | 0.7553 |
| HP [n, (%)] | 58 (79.5) | 18 (52.9) | 0.005 |
| FBG (mmol/L) | 7.21 ± 3.30 | 7.33 ± 3.05 | 0.649 |
| HbAlC (%) | 7.47 ± 1.70 | 7.69 ± 2.16 | 0.456 |
| TC (mmol/L) | 4.38 ± 1.16 | 4.69 ± 1.05 | 0.375 |
| TG (mmol/L) | 1.45 ± 0.94 | 2.01 ± 1.07 | 0.012 |
| HDL-C (mmol/L) | 1.23 ± 0.28 | 1.21 ± 0.41 | 0.830 |
| LDL-C (mmol/L) | 2.53 ± 0.89 | 2.57 ± 0.79 | 0.284 |
| UA (umol/L) | 335.16 ± 99.02 | 321.13 ± 91.65 | 0.501 |
| Cr (umol/L) | 80.07 ± 17.71 | 74.29 ± 25.65 | 0.655 |
The difference was compared using the independent sample t test or χ2 test
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TZD thiazolidinedione, CCB Calcium Channel Blocker, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, HP hypertension, FBG fast blood glucose, HbA1C hemoglobin A1c, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, UA uric acid, Cr Creatinine